Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles Ferté

Showing results (1-10 of 53) with videos related to

Pageof 6
Sort By:
European Journal of Cancer (Oxford, England : 1990)|April 8, 2017
iRECIST: A clarification of tumour response assessment in the immunotherapy eraCharles Ferté, Aurélien Marabelle
European Journal of Cancer (Oxford, England : 1990)|September 15, 2014
Should we resist to including tumour growth patterns in Response Evaluation Criteria in Solid Tumours evaluation? (Response to Litière et al.)Loic Verlingue, Serge Koscielny, Charles Ferté
Investigational New Drugs|May 9, 2009
Phase II trials in patients with carcinoma of unknown primary: a pooled data analysisAntoine Adenis, Charles Ferté, Nicolas Penel
Nature Reviews. Clinical Oncology|June 17, 2010
Molecular circuits of solid tumors: prognostic and predictive tools for bedside useCharles Ferté, Fabrice André, Jean-Charles Soria
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2014
TGR analysis in phase I clinical trials--responseCharles Ferté, Serge Koscielny, Jean-Charles Soria
Oncology|April 2, 2010
Individual life expectancy estimation using validated prognostic scores for patients with cancer of unknown primaryCharles Ferté, Nicolas Penel, Jacques Bonneterre, et al.
European Journal of Cancer (Oxford, England : 1990)|January 7, 2015
Systemic treatment of advanced hepatocellular carcinoma: from disillusions to new horizonsAntoine Hollebecque, David Malka, Charles Ferté, et al.
Cancer Discovery|November 5, 2014
Social interactomes for enabling research communitiesJustin Guinney, Rodrigo Dienstmann, Charles Ferté, et al.
American Journal of Clinical Oncology|March 22, 2012
Trastuzumab-induced cardiotoxicity: is it time for troponin for all patients?Charles Ferté, Christophe Massard, Ariel Cohen, et al.
European Journal of Cancer (Oxford, England : 1990)|June 20, 2017
Matching genomic molecular aberrations with molecular targeted agents: Are biliary tract cancers an ideal playground?Loic Verlingue, Antoine Hollebecque, Valérie Boige, et al.
Pageof 6

Showing results (1-10 of 53) with videos related to

Sort By:
Pageof 6
European Journal of Cancer (Oxford, England : 1990)|April 8, 2017
iRECIST: A clarification of tumour response assessment in the immunotherapy eraCharles Ferté, Aurélien Marabelle
European Journal of Cancer (Oxford, England : 1990)|September 15, 2014
Should we resist to including tumour growth patterns in Response Evaluation Criteria in Solid Tumours evaluation? (Response to Litière et al.)Loic Verlingue, Serge Koscielny, Charles Ferté
Investigational New Drugs|May 9, 2009
Phase II trials in patients with carcinoma of unknown primary: a pooled data analysisAntoine Adenis, Charles Ferté, Nicolas Penel
Nature Reviews. Clinical Oncology|June 17, 2010
Molecular circuits of solid tumors: prognostic and predictive tools for bedside useCharles Ferté, Fabrice André, Jean-Charles Soria
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2014
TGR analysis in phase I clinical trials--responseCharles Ferté, Serge Koscielny, Jean-Charles Soria
Oncology|April 2, 2010
Individual life expectancy estimation using validated prognostic scores for patients with cancer of unknown primaryCharles Ferté, Nicolas Penel, Jacques Bonneterre, et al.
European Journal of Cancer (Oxford, England : 1990)|January 7, 2015
Systemic treatment of advanced hepatocellular carcinoma: from disillusions to new horizonsAntoine Hollebecque, David Malka, Charles Ferté, et al.
Cancer Discovery|November 5, 2014
Social interactomes for enabling research communitiesJustin Guinney, Rodrigo Dienstmann, Charles Ferté, et al.
American Journal of Clinical Oncology|March 22, 2012
Trastuzumab-induced cardiotoxicity: is it time for troponin for all patients?Charles Ferté, Christophe Massard, Ariel Cohen, et al.
European Journal of Cancer (Oxford, England : 1990)|June 20, 2017
Matching genomic molecular aberrations with molecular targeted agents: Are biliary tract cancers an ideal playground?Loic Verlingue, Antoine Hollebecque, Valérie Boige, et al.
Pageof 6